A Pilot Study of Exenatide Actions in Alzheimer's Disease.

ABSTRACT:

Background

Strong preclinical evidence suggests that exenatide, a glucagon-like peptide-1 (GLP- 1) receptor agonist used for treating type 2 diabetes, is neuroprotective and disease-modifying in Alzheimer's Disease (AD).

Objective

We performed an 18-month double-blind randomized placebo-controlled Phase II clinical trial to assess the safety and tolerability of exenatide and explore treatment responses for clinical, cognitive, and biomarker outcomes in early AD.

Method

Eighteen participants with high probability AD based on cerebrospinal fluid (CSF) biomarkers completed the entire study prior to its early termination by the sponsor; partial outcomes were available for twentyone.

Results

Exenatide was safe and well-tolerated, showing an expectedly higher inciden

SUBMITTER: Mullins RJ 

PROVIDER: S-EPMC7476877 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature